HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

May 31st 2023

Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.

Dr Hilton on the Potential Impact of the CompassHER2-pCR Trial in HER2+ Breast Cancer

May 30th 2023

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Dr Hilton on the Impact of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 19th 2023

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast Cancer

May 17th 2023

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

May 17th 2023

Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.

Integrating the Latest Data Into Best Practices for Patients With HER2+ Breast Cancer

May 16th 2023

Nusayba Bagegni, MD, details ongoing research and possibilities for the treatment landscape in the future, which includes investigating escalating approaches through more research in clinical trials.

FDA Issues Complete Response Letter for Trastuzumab Duocarmazine in Advanced HER2+ Breast Cancer

May 15th 2023

The FDA has issued a complete response letter to the biologics license application for vic-trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.

Neoadjuvant Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Shows High pCR Rate in Early HER2+ Breast Cancer

May 12th 2023

Preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab led to improved rates of pathologic complete response and decreased residual cancer burden compared with trastuzumab, pertuzumab, and chemotherapy alone in patients with early-stage HER2-positive breast cancer, according to findings from the randomized phase 2 ATHENE trial.

Trastuzumab Deruxtecan Elicits Superior HRQOL in HER2+ Metastatic Breast Cancer

May 11th 2023

Patient-reported outcomes with fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial, according to findings presented during the 2023 ESMO Breast Cancer Annual Congress.

Toxicity Profile With Trastuzumab Deruxtecan Proves Consistent, Manageable in HER2-Low Metastatic Breast Cancer

May 11th 2023

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.

Dr Desai on Toxicities Associated with T-DXd in HER2+ Breast Cancer

May 10th 2023

Neelam Desai, MD, discusses the toxicity profile of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 5th 2023

Nusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Dr Bagegni on Updated APT and ATEMPT Results in Early-stage HER2+ Breast Cancer

May 3rd 2023

Nusayba Bagegni, MD, discusses updated efficacy and biomarker data from the phase 2 APT and ATEMPT trials in early-stage HER2-positive breast cancer.

Dr Graff on the Evaluation of Trastuzumab Deruxtecan in HER2-Zero Breast Cancer

April 12th 2023

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

NHS Scotland Grants Trastuzumab Deruxtecan Approval for Use in Pretreated HER2+ Metastatic Breast Cancer

April 12th 2023

The Scottish Medicines Consortium has accepted fam-trastuzumab deruxtecan-nxki as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy.

Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

April 11th 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Research on Current and Emerging HER2-targeted Agents Continues to Advance Breast Cancer Treatment

April 11th 2023

Cynthia X. Ma, MD, PhD, discusses updates in triple-negative breast cancer treatment, recent data on HER2-targeted agents in metastatic and early-stage HER2-positive breast cancer, and the role of CDK4/6 inhibitors and oral selective estrogen receptor degraders in hormone receptor–positive disease.

Novel Tucatinib-based Regimens Highlight Ongoing Research in HER2+ Breast Cancer

April 10th 2023

Jennifer M. Matro, MD, discusses the real-world implications and uptake of the HER2CLIMB regimen, other trials investigating tucatinib-based regimens in HER2-positive metastatic breast cancer, and how approaches differ between early-stage and metastatic hormone receptor–positive/HER2-negative breast cancer.

Dr Fenton on Trastuzumab Deruxtecan Vs Trastuzumab Emtansine in HER2+ Breast Cancer

April 7th 2023

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast03 trial in patients with metastatic, HER2-positive breast cancer.